S&P Futures
4,260.00 -4.75 (-0.11%) Dow Futures
33,188.00 -13.00 (-0.04%) Nasdaq Futures
14,684.25 -30.25 (-0.21%) Russell 2000 Futures
1,738.40 -3.50 (-0.20%) Crude Oil
87.66 -1.57 (-1.76%) Gold
1,837.30 -4.20 (-0.23%)
Sihuan Pharmaceutical Holdings Group Ltd (TEL1.SG)
Chart Events
Performance Outlook
| Previous Close | 0.0605 |
| Open | 0.0595 |
| Bid | 0.0620 x 526800000 |
| Ask | 0.0780 x 352300000 |
| Day's Range | 0.0595 - 0.0595 |
| 52 Week Range | 0.0595 - 0.1300 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TEL1.SG
Related Research
PR NewswireXuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"), a non-wholly owned subsidiary of Company, has received a drug registration approval from the National Medical Products Administration (the "NMPA") of China of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer. It is the first drug approved for marketing by Xuanzhu Biopharm, which marks a new milestone for Xuanzhu
PR NewswireSihuan Pharmaceutical（0460.HK）: Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing
Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; stock code: 0460) is pleased to announce that the Group's Jilin Huisheng Biopharmaceutical Co., Ltd. ("Huisheng Biopharmaceutical"), a non-wholly owned subsidiary, has successfully completed the acquisition of Jilin Baixing Bairong Investment Center (Limited Partnership)* ("Baixing Bairong"), JiLin Province Private Equity Co., Ltd. ("J
